Zacks Investment Research lowered shares of Zynex (OTCMKTS:ZYXI) from a buy rating to a hold rating in a research note released on Saturday morning.

According to Zacks, “Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company’s product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. “

Separately, ValuEngine cut shares of Zynex from a buy rating to a hold rating in a research report on Tuesday, October 31st.

Zynex (OTCMKTS ZYXI) opened at $4.28 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.27 and a quick ratio of 1.19. The firm has a market cap of $145.45, a PE ratio of 32.92 and a beta of 0.54. Zynex has a 52 week low of $0.26 and a 52 week high of $5.50.

Zynex (OTCMKTS:ZYXI) last posted its quarterly earnings results on Monday, November 13th. The company reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.01. The firm had revenue of $6.82 million for the quarter, compared to the consensus estimate of $5.52 million. Zynex had a net margin of 24.10% and a negative return on equity of 248.78%. research analysts anticipate that Zynex will post 0.22 EPS for the current year.

WARNING: “Zacks Investment Research Lowers Zynex (ZYXI) to Hold” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at

About Zynex

Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with's FREE daily email newsletter.